31 Oct, EOD - Indian

SENSEX 79389.06 (-0.69)

Nifty 50 24205.35 (-0.56)

Nifty Bank 51475.35 (-0.64)

Nifty IT 40407.55 (-3.03)

Nifty Midcap 100 56112.85 (-0.40)

Nifty Next 50 69911.75 (-0.51)

Nifty Pharma 22735.55 (1.61)

Nifty Smallcap 100 18602.6 (1.15)

31 Oct, EOD - Global

NIKKEI 225 39081.25 (-0.50)

HANG SENG 20317.33 (-0.31)

S&P 5730.97 (-1.51)

Login/Signup
LOGIN HERE
Cancel

Fortis Healthcare Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532843 | NSE Symbol : FORTIS | ISIN : INE061F01013 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
04-Oct-2024 09-Oct-2024 Issue of Debentures FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/10/2024 inter alia to consider and approve the issue of Non-Convertible Debentures (NCD) Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations,2015 (As Per BSE Announcement dated on 09.10.2024)
27-Aug-2024 30-Aug-2024 Raising funds through Debt Instr. FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/08/2024 inter alia to consider and approve the proposal of raising of fund through permissible mode(s) The relevant disclosure relating to Outcome of Board Meeting held on August 30, 2024 is attached. (As Per BSE Announcement dated on 30.08.2024)
30-Jul-2024 06-Aug-2024 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve un-audited financial results for the quarter ended June 30 2024 Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 for Change in Director Outcome of Board Meeting for the quarter ended June 30, 2024 The relevant Disclosure is attached Disclosure under Regulation 30 of SEBI (LODR) Regulation 2015 for appointment of BSR & Co LLP , Chartered Accountant as a Tax Auditor for the FY 2023-24 (As Per BSE Announcement Dated on 06.08.2024)
05-Jul-2024 05-Jul-2024 Change in Directors Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with SEBI Circular dated July 13, 2023, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. July 5, 2024 have, inter-alia, considered and recommended/ approved the following: a) Designated Dr. Prem Kumar Nair (a Non- Executive Director) as the Vice-Chairman of the Board of the Company. b) Recommended re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director (designated as Managing Director & Chief Executive Officer) for a further period of two years effective from March 19, 2025, not liable to retire by rotation; and The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure-A.
16-May-2024 23-May-2024 Accounts FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday May 23 2024 inter-alia to: a) consider and approve audited financial results of the Company for the quarter and financial year ended March 31 2024; and b) consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2024. Further in continuation to our letter ref. FHL/SEC/2023-24 dated March 27 2024 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till May 25 2024. Outcome of Board Meeting May 23, 2024, please find the detailed disclosure enclosed. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. May 23, 2024, inter-alia, has considered and approved Financial Results, Dividend, Re-appointment of Statutory Auditors and Appointment of Cost Auditor for Financial Year 2024-25 as per detailed disclosure enclosed. Board has recommended the final dividend as per detailed disclosure enclosed. Subject to the approval of shareholders of the Company in the ensuing AGM the Board has re-appointed the statutory auditors of the Company, as per detailed disclosure enclosed. (As Per BSE Announcement Dated on 23.05.2024)
13-Mar-2024 13-Mar-2024 Change in Auditors Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with SEBI Circular dated July 13, 2023, this is to inform you that the Board of Directors of the Company in their meeting held today i.e. March 13, 2024 have, inter-alia, considered and approved the appointment of Mr. Sanjay Baweja as Chief Internal Audit and Risk Officer of the Company, with effect from March 13, 2024. The detailed disclosure is enclosed. Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, this is to inform you that Mr. Sanjay Baweja appointed as Chief Internal Audit and Risk Officer of the Company, the detailed disclosure is enclosed.
01-Mar-2024 01-Mar-2024 Change in Other Executives Pursuant to Regulation 30 of SEBI LODR Regulation, 2015, this is to inform you that Mr. Murlee Manohar Jain has resigned from the position of Company Secretary & Compliance Officer of the Company and Mr. Satyendra Chauhan appointed as Company Secretary & Compliance Officer of the Company, as per detailed disclosure enclosed. This is to inform you that the Board of Directors of the Company at its meeting held today i.e. March 1, 2024 have, inter-alia, considered the following: a) Noting of resignation of Mr. Murlee Manohar Jain from the position of Company Secretary & Compliance Officer of the Company with effect from February 29, 2024 (close of business hours). b) Approved the appointment of Mr. Satyendra Chauhan as Company Secretary & Compliance Officer of the Company with effect from March 1, 2024. The detailed disclosure is attached. This is for your information and record.
31-Jan-2024 07-Feb-2024 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2024 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday February 7 2024 to inter-alia consider and approve un-audited financial results for the quarter and period ended December 31 2023. Further in continuation to our letter ref. FHL/SEC/2023-24 dated December 27 2023 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till February 9 2024. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 7, 2024, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2023. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditors of the Company for the quarter and period ended on December 31, 2023. This is for your information and record. (As per BSE Announcement Dated on 07/02/2024)
03-Nov-2023 10-Nov-2023 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (LODR) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday November 10 2023 to inter-alia consider and approve un-audited financial results for the quarter and period ended September 30 2023. Further in continuation to our letter ref. FHL/SEC/2023-24 dated September 29 2023 captioned 'Closure of Trading Window' it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till November 12 2023. The Board of Director of the Company in their meeting held on November 10, 2023 inter-alia considered and approved the standalone and consolidated unaudited financial results for the quarter and period ended September 30, 2023. Copies of the said financial results along with limited review reports are attached. (As per BSE Announcement Dated on 10/11/2023)
28-Jul-2023 04-Aug-2023 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday August 4 2023 to inter-alia consider and approve un-audited financial results for the quarter ended June 30 2023. Further in continuation to our letter ref. FHL/SEC/2023-24 dated June 29 2023 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till August 6 2023. Pursuant to regulation 30 of SEBI LODR and in furtherance of the Contractual obligations contained in Shareholders Agreement executed on June 12, 2012(as amended vide amendment agreement dated March 30, 2021) as previously disclosed , this is to inform you that the Board of Directors of the Company and the Board of Directors of the Agilus Diagnostics Limited, in their respective meetings held today i.e. August 4, 2023, have considered and granted its confirmation/approval for Agilus to initiate an Initial Public Offer process, by way of offer of sale. The detailed disclosures in this regard is enclosed herewith. (As Per BSE Announcement Dated on 04.08.2023)
16-May-2023 23-May-2023 Accounts FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Tuesday May 23 2023 inter-alia to: a) consider and approve audited financial results of the Company for the quarter and financial year ended March 31 2023; and b) consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2023. Further in continuation to our letter ref. FHL/SEC/2022-23 dated March 30 2023 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till May 25 2023. This is to inform you that the Board of Directors of the Company at its meeting held today i.e. May 23, 2023, inter-alia, has: a)Considered and approved the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2023. M/s B S R and Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion. b) Considered and recommended a final dividend of ? 1 /- per equity share (10% of face value of ? 10 /- each), for the financial year 2022-23, subject to approval of the members of the Company, which shall be paid/ dispatched within 30 days from the conclusion of the ensuing Annual General Meeting. This is to inform you that the Board of Directors of the Company at its meeting held today i.e. May 23, 2023, inter-alia, has: a)Considered and approved the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2023. M/s B S R and Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion. b) Considered and recommended a final dividend of ? 1 /- per equity share (10% of face value of ? 10 /- each), for the financial year 2022-23, subject to approval of the members of the Company, which shall be paid/ dispatched within 30 days from the conclusion of the ensuing Annual General Meeting. (As per BSE Announcement Dated on 23/05/2023)
03-Feb-2023 10-Feb-2023 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday February 10 2023 to inter-alia consider and approve un-audited financial results for the quarter ended December 31 2022. Further in continuation to our letter ref. FHL/SEC/2022-23 dated December 29 2022 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till February 12 2023. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. The meeting commenced at 1100 Hours IST and concluded at 1930 Hours IST Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. (As Per BSE Announcement dated on 10.02.2023)
03-Nov-2022 11-Nov-2022 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday November 11 2022 to inter-alia consider and approve un-audited financial results for the quarter and period ended September 30 2022. Further in continuation to our letter ref. FHL/SEC/2022-23 dated September 29 2022 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till November 13 2022. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 11, 2022, inter-alia, considered and approved standalone and consolidated un-audited financial results of the Company for the qua1ter and period ended on September 30, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the qua1ter and period ended on September 30, 2022. Fu1ther, a copy of the press release and investor presentation being issued in this regard is also enclosed. · The meeting commenced at 0900 Hours 1ST and concluded at 1800 Hours 1ST. (As Per BSE Announcement dated on 11.11.2022)
28-Jul-2022 05-Aug-2022 Quarterly Results FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday August 5 2022 to inter-alia consider and approve un-audited financial results for the quarter ended June 30 2022. Further in continuation to our letter ref. FHL/SEC/2022-23 dated June 29 2022 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till August 7 2022. This is for your information and record. Dear Madam / Sir, Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 5, 2022, inter-alia, considered and approved the following: (i) Standalone and Consolidated un-audited financial results of the Company for the quarter ended on June 30, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter ended on June 30, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. (ii) Amalgamation of Fortis Asia Healthcare Pte Limited ('FAHPL') and Fortis Healthcare International Pte Limited ('FHIPL'), step-down wholly-owned subsidiaries of the Company. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 5, 2022, inter-alia, considered and approved the following: Standalone and Consolidated un-audited financial results of the Company for the quarter ended on June 30, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter ended on June 30, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. (As per BSE Announcement Dated on 05/08/2022)
18-May-2022 25-May-2022 Accounts FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday May 25 2022 to inter-alia consider and approve audited financial results for the quarter and year ended March 31 2022. Further in continuation to our letter ref. FHL/SEC/2021-22 dated March 30 2022 captioned Closure of Trading Window it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till May 27 2022. Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. May 25, 2022, inter-alia, considered and approved the following: (i) Audited Standalone and Consolidated Financial results of the Company for the quarter and financial year ended March 31, 2022. M/s B S R and Co. LLP, the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion. (ii) Re-appointment of Mr. Ravi Rajagopal, Ms. Suvalaxmi Chakraborty and Mr. Indrajit Banerjee as Independent Directors of the Company, subject to approval of the shareholders, for the second term of upto 5 years. (As Per BSE Announcement Dated on 25.05.2022) Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held on May 25, 2022 have, inter-alia, authorised Key Managerial Personnel of the Company for the purpose of determining materiality of an event or information and for the purpose of making disclosures to the Stock Exchanges. This is for your information and record. Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held on May 25, 2022 have, inter-alia, considered and approved the Re-appointment of Mr. Ravi Rajagopal, Ms. Suvalaxmi Chakraborty and Mr. Indrajit Banerjee as Independent Directors of the Company, subject to approval of the shareholders, for the second term of upto 5 years. Further, the detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFD /CMD/4/2015 dated September 9, 2015 is enclosed. (As Per BSE Announcement Dated on 26/05/2022)
1 2